title: Efficacy of a specific polyclonal equine F(ab')2 against avian influenza (H5N1) in ferrets: synergy with oseltamivir.
abstract: Current therapies against avian influenza (H5N1) provide limited clinical benefit. FBF-001 is a highly purified equine polyclonal immunoglobulin fragment against H5N1.
  
  
  
  Using a ferret model of severe acute H5N1 infection, we assessed FBF-001 when administered on the same day or 1 day after viral challenge, in comparison with oseltamivir therapy.
  
  
  
  Untreated animals died 2-3 days after challenge. FBF-001 prevented most severe illness and reduced nasal viral load, with best efficacy when administered on the day of viral challenge. Oseltamivir and FBF-001 had synergistic impact on survival.
  
  
  
  FBF-001 prevented severe consequences of lethal H5N1 challenge in ferrets by controlling viral replication, an effect synergistic to oseltamivir. FBF-001 has recently been granted EMA orphan drug status.
authors.affiliation: Fab'entech, 24, rue Jean Baldassini - Bâtiment B, 69007 Lyon, France.
authors.forename: Cécile H
authors.initials: CH
authors.lastname: Herbreteau
authors.affiliation: Fab'entech, 24, rue Jean Baldassini - Bâtiment B, 69007 Lyon, France.
authors.forename: Mélanie
authors.initials: M
authors.lastname: Denizot
authors.affiliation: CSIRO Australian Animal Health Laboratory, Geelong, Victoria, Australia.
authors.forename: Suzanne
authors.initials: S
authors.lastname: Lowther
authors.affiliation: CSIRO Australian Animal Health Laboratory, Geelong, Victoria, Australia.
authors.forename: Sarah
authors.initials: S
authors.lastname: Riddell
authors.affiliation: CSIRO Australian Animal Health Laboratory, Geelong, Victoria, Australia.
authors.forename: Leah
authors.initials: L
authors.lastname: Frazer
authors.affiliation: CSIRO Australian Animal Health Laboratory, Geelong, Victoria, Australia.
authors.forename: Jessica
authors.initials: J
authors.lastname: Haining
authors.affiliation: CSIRO Australian Animal Health Laboratory, Geelong, Victoria, Australia.
authors.forename: Rachel
authors.initials: R
authors.lastname: Arkinstall
authors.affiliation: CSIRO Australian Animal Health Laboratory, Geelong, Victoria, Australia.
authors.forename: Jean
authors.initials: J
authors.lastname: Payne
authors.affiliation: CSIRO Australian Animal Health Laboratory, Geelong, Victoria, Australia.
authors.forename: Jenni
authors.initials: J
authors.lastname: Harper
authors.affiliation: CSIRO Australian Animal Health Laboratory, Geelong, Victoria, Australia.
authors.forename: Dayna
authors.initials: D
authors.lastname: Johnson
authors.affiliation: Fab'entech, 24, rue Jean Baldassini - Bâtiment B, 69007 Lyon, France.
authors.forename: Anaïs
authors.initials: A
authors.lastname: Pasquier
authors.affiliation: CSIRO Australian Animal Health Laboratory, Geelong, Victoria, Australia.
authors.forename: Deborah
authors.initials: D
authors.lastname: Middleton
authors.affiliation: Fab'entech, 24, rue Jean Baldassini - Bâtiment B, 69007 Lyon, France.
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Saluzzo
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005289:Ferrets; D006736:Horses; D007116:Immunization, Passive / Q000379:methods*; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D053124:Influenza A Virus, H5N1 Subtype / Q000502:physiology*; D009965:Orphan Drug Production; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000628:therapy*; D053139:Oseltamivir / Q000627:therapeutic use*; D019562:Viral Load
chemical_list: D000914:Antibodies, Viral; D000998:Antiviral Agents; D007140:Immunoglobulin Fab Fragments; D053139:Oseltamivir
keywords: A/H5N1; F(ab')2; avian influenza; ferret; immunoglobulin; oseltamivir